MaxCyte
CRISPR-Cas9 gene editing pioneer secures licenceBerGenBio
NOK500m raised to drive bemcentinib progressMaxCyte
£25.1m ($31.0m) successully raisedNexstim
€2.3m rights issue to progress both NBS and NBTHutchison China MediTech
AACR 2020: first surufatinib/PD-1 combo dataBerGenBio
Bemcentinib fast-tracked into COVID-19 trialMaxCyte
FY19 results crown a breakthrough yearHutchison China MediTech
Weathering the COVID-19 stormHutchison China MediTech
Laying the foundations for a new eraNexstim
Patient registry shows promising outcomes in MDD